More for AtCor
Thursday, 24 July, 2008
AtCor Medical [ASX: ACG] has reached new supply agreements for its SphygmoCor blood-pressure measurement systems.
The contracts are worth at least a combined $1.66 million. AtCor has secured $2.8 million worth of contracts in the past 60 days.
SphygmoCor is a blood pressure monitoring system that identifies the effects of reflected blood pressure in the central aortic pressure wave.
The company has sold over 1,400 SphygmoCors to medical institutions and research institutions conducting clinical trials, as the device can be used to measure the effects of medication on central blood pressure.
Protein-based therapy helps the body remove harmful cells
Scientists have created a protein-based therapeutic tool that could change the way we treat...
Diabetes changes the structure of our hearts, study finds
Type 2 diabetes directly alters the heart's structure and energy systems, which explains why...
Beta blockers could halt triple negative breast cancer
Researchers have identified a molecular biomarker in triple negative breast cancer tumours which...
